

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## 东曜药业

### TOT BIOPHARM International Company Limited

東曜藥業股份有限公司

*(Incorporated in Hong Kong with limited liability)*

**(Stock code: 1875)**

### **FURTHER DELAY IN DISPATCH OF CIRCULAR IN RESPECT OF CONNECTED TRANSACTIONS INVOLVING SUBSCRIPTION BY TWO INVESTORS FOR NEW SHARES TO BE ISSUED UNDER SPECIFIC MANDATE**

Reference is made to the announcement of TOT BIOPHARM International Company Limited (the “**Company**”) dated 31 May 2022 in relation to the connected transactions involving the allotment and issue of the Subscription Shares to Centerlab and Vivo Suzhou Fund, and the announcement of the Company dated 22 June 2022 in relation to the delay in dispatch of the Circular (as defined below) (collectively, the “**Announcements**”). Unless otherwise stated, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

As set out in the Announcements, a circular (the “**Circular**”) containing, among other things, (i) further details of the Subscriptions and the allotment and issue of the Subscription Shares; (ii) a letter of opinion from the independent Board committee; (iii) a letter of advice from the independent financial adviser; and (iv) the notice of the Extraordinary General Meeting, was expected to be dispatched to the Shareholders on or before 30 June 2022.

The content of the Circular has been substantially finalized. However, as additional time is required for the final-checking and bulk-printing of the Circular, the Company now expects to dispatch the Circular to the Shareholders on 5 July 2022.

By order of the Board  
**TOT BIOPHARM International Company Limited**  
**Dr. Liu, Jun**  
*Chief Executive Officer and Executive Director*

Hong Kong, 30 June 2022

*As at the date of this announcement, the executive directors of the Company are Dr. Liu, Jun and Ms. Yeh-Huang, Chun-Ying; the non-executive directors of the Company are Mr. Fu, Shan and Mr. Qiu, Yu Min; and the independent non-executive directors of the Company are Ms. Hu, Lan, Mr. Chang, Hong-Jen and Dr. Wang, De Qian.*